Skip to main content

Table 1 Effects of CNX-011-67 on blood HbA1c, Fructosamine, PDX1 and apoptotic positive cells

From: Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats

Parameters       Groupings  
Lean control ZDF control CNX-011-67 (5 mg/kg)
HbA1c 3.84 ± 0.08 5.50 ± 0.30 5.18 ± 0.11
Fructosamine 92.47 ± 10.68 236.36 ± 19.08 111.25 ± 10.61**
HOMA-IR 2.16 ± 0.74 64.26 ± 6.18 41.82 ± 2.59*
HOMA-beta 117.34 ± 39.35 1520.20 ± 227.30 2206.79 ± 418.69
PDX1 positive cells 650 ± 49 461 ± 47.50 589 ± 43
Apoptotic cells 00 ± 00 47 ± 8.7 29 ± 4.6
  1. Data in all panels are mean ± SEM (n = 10/group). Statistical comparison was conducted by One-way ANOVA with Dunnett’s post test correction to arrive at the significance level when compared with ZDF control. (*p < 0.05 and **p < 0.01).
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us